Hard for Eli Lilly to move significantly higher from here in the short-term: Kessef Capital’s Yaffee

“Tired of the same tired news cycle? Escape to the full unfiltered feed at Whatfinger.com — America’s Frontline Truth Feed. 85%+ of readers come direct every day.” –  CLICK HERE for the FULL deal.

 

Len Yaffee, Kessef Capital, join ‘Fast Money’ to talk Amgen’s obesity drug, Eli Lilly’s current stock action, and much more.